---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004422"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:19:27.294525+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q2 ORLADEYO revenue up 34% to $108.3M; raises FY guidance to $420-435M

## Summary
- Q2 total revenue $109.3M (+32.5% YoY); GAAP operating profit $8.8M vs loss $20.7M in Q2 2023.
- Net loss narrowed to $12.7M ($0.06/share) from $75.3M ($0.40/share); non-GAAP operating profit $21.9M.
- ORLADEYO FY2024 revenue guidance raised to $420-435M from $390-400M, citing strong demand and payer improvements.
- Discontinuing oral Factor D inhibitor BCX10013 due to insufficient activity; advancing BCX17725 for Netherton syndrome to clinic by end-2024.
- Cash $338.1M vs $415.7M a year ago; operating cash use was only $0.2M in Q2.

## SEC filing metadata
- accession: 0001171843-24-004422
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184324004422/0001171843-24-004422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184324004422/f8k_080524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004422
- JSON: https://secwatch.observer/filing/0001171843-24-004422.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.